The global gene expression analysis market size was estimated to be USD 4.98 billion in 2023 and is expected to reach at USD 12.75 billion by 2034 with a CAGR of 8.92% during the forecast period 2024-2034. Increasing focus development of technologically advanced solutions, rising gene expression studies, growing adoption of gene expression technique across various stages of the drug discovery process, surge in government funding for genomics, increasing adoption of personalized medicine, growing technological advancements, rising genetic disorders, and surge in launch of advanced products to accelerate genomic medicine are some of the key factors boosting the market growth.
Surge in launch of advanced products to accelerate genomic medicine is predicted to boost the market growth during the forecast period. Gene expression analysis has become a pivotal technology with broad applications across the drug development continuum, encompassing drug discovery, clinical diagnostics, biotechnology, microbiology, and more. The constraints associated with current technologies for disease detection and the creation of precise medications have driven a heightened need for novel technologies. For instance, in July 2023, Illumina, Inc. has unveiled the NovaSeq X Series, comprising the NovaSeq X and NovaSeq X Plus, which are advanced production-scale sequencers designed to expedite genomic medicine. This groundbreaking technology has the capability to produce over 20,000 complete genomes annually, marking a 2.5-fold increase in throughput compared to previous sequencing systems.
By process, cDNA synthesis & conversion was the highest revenue-grossing segment in the global gene expression analysis market in 2023 owing to the availability of several cDNA synthesis kits to accommodate research requirements for ideal reaction temperature, the quantity of reactions, & sample size, increasing product launches of cDNA synthesis & library preparation kits. Additionally, data analysis & interpretation is predicted to grow at fastest CAGR during the forecast period owing to rising technological advancements, surge in mergers & acquisitions within market players, increasing investment in research, growing demand for better interpretation software for cancer gene expression, and rising launch of advanced platforms by major market players. For instance, in January 2023, QIAGEN Digital Insights (QDI), the bioinformatics division of QIAGEN, has released the QIAGEN CLC Genomics Workbench Premium, a solution that addresses the data analysis slowdown in next-generation sequencing (NGS). This solution tackles the NGS data analysis bottleneck by introducing rapid analysis speed for processing and interpreting data from whole exome sequencing (WES), whole genome sequencing (WGS), and extensive panel sequencing.
By product, kits & reagents was the highest revenue-grossing segment in the global gene expression analysis market in 2023 owing to the existence of a large number of businesses providing various kits & reagents for gene expression, and growing introduction of advanced products. For instance, In July 2023, QIAGEN has unveiled an expansion of its next-generation sequencing (NGS) collection through the introduction of the QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kit. These innovations redefine the sample preparation process for accurately identifying nucleic acid sequences. Additionally, DNA chip/microarray is predicted to grow at fastest CAGR during the forecast period owing to the increased use of DNA microarrays for gene expression analysis and surge in technological advancements.
By technology, RNA expression was the highest revenue-grossing segment in the global gene expression analysis market in 2023 owing to the increasing technological advances in RNA expression tools & techniques coupled with the accessibility of a variety of items to satisfy various research demands, surge in genomic research, and growing investment in research & development activities. Additionally, next-generation sequencing is predicted to grow at fastest CAGR during the forecast period owing to the increasing use of next-generation sequencing technology in clinical diagnosis, expanding application of next-generation sequencing in a variety of disorders, escalating efforts by businesses, academic institutions, and research centers to use next-generation sequencing to provide efficient illness treatments & medicines, and rising launch of advanced technologies. For instance, in April 2022, Illumina has established a prolonged strategic partnership with Janssen Biotech aimed at expediting the advancement of precision medications. Within this collaboration, Illumina harnesses its range of assets, including artificial intelligence-driven genome interpretation tools, whole-genome sequencing, and multi-omic analysis services, to jointly develop companion diagnostic (CDx) initiatives using the TruSight Oncology Comprehensive assay. This assay is a single test that evaluates numerous tumor genes and biomarkers within a patient's cancer.
By application, drug discovery & development was the highest revenue-grossing segment in the global gene expression analysis market in 2023 owing to the increasing analysis of gene expression profiles, growing research & development activities for the innovation of novel treatments, and rising collaborations within market players. For instance, in October 2022, Illumina Inc. and AstraZeneca, a science-focused biopharmaceutical firm, have initiated a strategic research partnership aimed at expediting drug target discovery. Their collaboration combines their respective capabilities in artificial intelligence (AI)-driven genome interpretation, genomic analysis methods, and industry knowledge. Additionally, clinical diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for early & accurate diagnostic tests for complex disorders and surge in launch of advanced products.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising research & development activities for the development of gene therapy, increasing government initiatives, growing investment for next-generation sequencing (NGS) research, and surge in funding by major market players. For instance, in July 2022, Epic Bio, founded by the CRISPR Pioneer, has been unveiled and secured $55 million in funding. Epic Bio has created an innovative gene expression technology referred to as the GEMS (Gene Expression Modulation System) platform, enabling precise control over gene expression. The GEMS platform encompasses the most extensive collection of newly discovered gene expression modifiers, coupled with advanced computational genomics tools. These components are instrumental in the generation of guide RNAs for the modulation of target genes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of genetic disorders, rising adoption of sequencing & array technologies, increasing research on genomic & gene-related studies, surge in technological advancements, and rising collaborations within market players. For instance, in May 2022, Thermo Fisher Scientific and the Qatar Genome Program (QGP) have formed a partnership with the objective of expediting genomic research and the clinical use of predictive genomics in Qatar. This collaboration is a stride towards extending the advantages of precision medicine to Arab populations on a global scale.
Surge in launch of advanced products to accelerate genomic medicine is predicted to boost the market growth during the forecast period. Gene expression analysis has become a pivotal technology with broad applications across the drug development continuum, encompassing drug discovery, clinical diagnostics, biotechnology, microbiology, and more. The constraints associated with current technologies for disease detection and the creation of precise medications have driven a heightened need for novel technologies. For instance, in July 2023, Illumina, Inc. has unveiled the NovaSeq X Series, comprising the NovaSeq X and NovaSeq X Plus, which are advanced production-scale sequencers designed to expedite genomic medicine. This groundbreaking technology has the capability to produce over 20,000 complete genomes annually, marking a 2.5-fold increase in throughput compared to previous sequencing systems.
By process, cDNA synthesis & conversion was the highest revenue-grossing segment in the global gene expression analysis market in 2023 owing to the availability of several cDNA synthesis kits to accommodate research requirements for ideal reaction temperature, the quantity of reactions, & sample size, increasing product launches of cDNA synthesis & library preparation kits. Additionally, data analysis & interpretation is predicted to grow at fastest CAGR during the forecast period owing to rising technological advancements, surge in mergers & acquisitions within market players, increasing investment in research, growing demand for better interpretation software for cancer gene expression, and rising launch of advanced platforms by major market players. For instance, in January 2023, QIAGEN Digital Insights (QDI), the bioinformatics division of QIAGEN, has released the QIAGEN CLC Genomics Workbench Premium, a solution that addresses the data analysis slowdown in next-generation sequencing (NGS). This solution tackles the NGS data analysis bottleneck by introducing rapid analysis speed for processing and interpreting data from whole exome sequencing (WES), whole genome sequencing (WGS), and extensive panel sequencing.
By product, kits & reagents was the highest revenue-grossing segment in the global gene expression analysis market in 2023 owing to the existence of a large number of businesses providing various kits & reagents for gene expression, and growing introduction of advanced products. For instance, In July 2023, QIAGEN has unveiled an expansion of its next-generation sequencing (NGS) collection through the introduction of the QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kit. These innovations redefine the sample preparation process for accurately identifying nucleic acid sequences. Additionally, DNA chip/microarray is predicted to grow at fastest CAGR during the forecast period owing to the increased use of DNA microarrays for gene expression analysis and surge in technological advancements.
By technology, RNA expression was the highest revenue-grossing segment in the global gene expression analysis market in 2023 owing to the increasing technological advances in RNA expression tools & techniques coupled with the accessibility of a variety of items to satisfy various research demands, surge in genomic research, and growing investment in research & development activities. Additionally, next-generation sequencing is predicted to grow at fastest CAGR during the forecast period owing to the increasing use of next-generation sequencing technology in clinical diagnosis, expanding application of next-generation sequencing in a variety of disorders, escalating efforts by businesses, academic institutions, and research centers to use next-generation sequencing to provide efficient illness treatments & medicines, and rising launch of advanced technologies. For instance, in April 2022, Illumina has established a prolonged strategic partnership with Janssen Biotech aimed at expediting the advancement of precision medications. Within this collaboration, Illumina harnesses its range of assets, including artificial intelligence-driven genome interpretation tools, whole-genome sequencing, and multi-omic analysis services, to jointly develop companion diagnostic (CDx) initiatives using the TruSight Oncology Comprehensive assay. This assay is a single test that evaluates numerous tumor genes and biomarkers within a patient's cancer.
By application, drug discovery & development was the highest revenue-grossing segment in the global gene expression analysis market in 2023 owing to the increasing analysis of gene expression profiles, growing research & development activities for the innovation of novel treatments, and rising collaborations within market players. For instance, in October 2022, Illumina Inc. and AstraZeneca, a science-focused biopharmaceutical firm, have initiated a strategic research partnership aimed at expediting drug target discovery. Their collaboration combines their respective capabilities in artificial intelligence (AI)-driven genome interpretation, genomic analysis methods, and industry knowledge. Additionally, clinical diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for early & accurate diagnostic tests for complex disorders and surge in launch of advanced products.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising research & development activities for the development of gene therapy, increasing government initiatives, growing investment for next-generation sequencing (NGS) research, and surge in funding by major market players. For instance, in July 2022, Epic Bio, founded by the CRISPR Pioneer, has been unveiled and secured $55 million in funding. Epic Bio has created an innovative gene expression technology referred to as the GEMS (Gene Expression Modulation System) platform, enabling precise control over gene expression. The GEMS platform encompasses the most extensive collection of newly discovered gene expression modifiers, coupled with advanced computational genomics tools. These components are instrumental in the generation of guide RNAs for the modulation of target genes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of genetic disorders, rising adoption of sequencing & array technologies, increasing research on genomic & gene-related studies, surge in technological advancements, and rising collaborations within market players. For instance, in May 2022, Thermo Fisher Scientific and the Qatar Genome Program (QGP) have formed a partnership with the objective of expediting genomic research and the clinical use of predictive genomics in Qatar. This collaboration is a stride towards extending the advantages of precision medicine to Arab populations on a global scale.
Segmentation: Gene Expression Analysis Market Report 2022 - 2033
Gene Expression Analysis Market Analysis & Forecast by Process 2023 - 2034 (Revenue USD Bn)
- PCR Analysis
- Sample Collection
- cDNA Synthesis & Conversion
- Purification
- Data Analysis & Interpretation
Gene Expression Analysis Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- DNA Chip/Microarray
- Kits & Reagents
- Others
Gene Expression Analysis Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Microarrays
- RNA-Sequencing
- PCR Techniques
- Next-Generation Sequencing
Gene Expression Analysis Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Clinical Diagnostics
- Drug Discovery & Development
- Biotechnology & Microbiology
- Others
Gene Expression Analysis Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Gene Expression Analysis Market: Process Estimates & Trend Analysis
8. Gene Expression Analysis Market: Product Estimates & Trend Analysis
9. Gene Expression Analysis Market: Technology Estimates & Trend Analysis
10. Gene Expression Analysis Market: Application Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Gene Expression Analysis Market
13. Europe Global Gene Expression Analysis Market
14. Asia Pacific Global Gene Expression Analysis Market
15. Latin America Global Gene Expression Analysis Market
16. MEA Global Gene Expression Analysis Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- QIAGEN
- Interpace Biosciences Inc.
- F. Hoffmann-La Roche Ltd.
- Biocartis NV
- Danaher Corp.
- PerkinElmer Inc.
- ELITechGroup
- Agilent Technologies
- Illumina Inc.
- Promega Corp.
- Quest Diagnostics Inc.
- Fluidigm Corp.
- Luminex Corp.
- Bio-Rad Laboratories
- IntegraGen
- Takara Bio Inc.
- GE Healthcare
- AutoGenomics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.98 Billion |
| Forecasted Market Value ( USD | $ 12.75 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
